Page last updated: 2024-11-12

ethidium homodimer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethidium homodimer: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12328896
CHEMBL ID2159003
MeSH IDM0070159

Synonyms (7)

Synonym
ethidium homodimer
61926-22-5
ethidium homodimer-1
CHEMBL2159003 ,
mfcd18433392
bdbm50485722
5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride

Research Excerpts

Overview

The ethidium homodimer-1 is a high-affinity red fluorescent DNA dye that is internalized only through altered cell membranes. It has been widely used to identify necrotic cells in culture.

ExcerptReferenceRelevance
"Ethidium homodimer is a cell-membrane impermeant nuclear fluorochrome that has been widely used to identify necrotic cells in culture. "( A novel method for the evaluation of proximal tubule epithelial cellular necrosis in the intact rat kidney using ethidium homodimer.
Diamantakos, EA; Edwards, JR; Lamar, PC; Peuler, JD; Prozialeck, WC, 2007
)
1.99
"The ethidium homodimer-1 is a high-affinity red fluorescent DNA dye that is internalized only through altered cell membranes."( Measurement of tumor necrosis factor activity by flow cytometry.
Lévesque, A; Pagé, M; Paquet, A, 1995
)
0.77

Dosage Studied

ExcerptRelevanceReference
"Cytotoxicity assessments of nanomaterials, such as silver nanoparticles, are challenging due to interferences with test reagents and indicators as well uncertainties in dosing as a result of the complex nature of nanoparticle intracellular accumulation."( Intracellular accumulation and dissolution of silver nanoparticles in L-929 fibroblast cells using live cell time-lapse microscopy.
Casey, BJ; Celedon, A; Goering, PL; Hussain, SM; Maurer, EI; Nagy, AM; Wildt, BE, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)3.60360.00011.076810.0000AID695926; AID695927; AID696085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID695927Inhibition of HIV-1 reverse transcriptase using 0.05 ug/mL of Poly(rA).p(dT) (12 to 18) as substrate after 30 mins by single point PCR assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Inhibition of therapeutically important polymerases with high affinity bis-intercalators.
AID696085Inhibition of HIV-1 reverse transcriptase using 25 ug/mL of Poly(rA).p(dT) (12 to 18) as substrate after 30 mins by single point PCR assay in presence of 340 uM base pair of calf thymus DNA2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Inhibition of therapeutically important polymerases with high affinity bis-intercalators.
AID695928Ratio of IC50 for HIV-1 reverse transcriptase using 0.05 ug/mL of Poly(rA).p(dT) (12 to 18) as substrate to IC50 for HIV-1 reverse transcriptase using 25 ug/mL of Poly(rA).p(dT) (12 to 18) as substrate2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Inhibition of therapeutically important polymerases with high affinity bis-intercalators.
AID695926Inhibition of HIV-1 reverse transcriptase using 25 ug/mL of Poly(rA).p(dT) (12 to 18) as substrate after 30 mins by single point PCR assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Inhibition of therapeutically important polymerases with high affinity bis-intercalators.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (83)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (6.02)18.7374
1990's21 (25.30)18.2507
2000's39 (46.99)29.6817
2010's18 (21.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.65 (24.57)
Research Supply Index4.49 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index59.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other87 (98.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]